drugset / Trial / NCT05256901

Sugammadex vs Neostigmine Reversal in Pediatric Appendectomy

NCT05256901

Phase 4 Terminated 22 enrolled Emory University
RandomizedParallel-groupSingle-blindOther

Summary

This study is designed as a randomized controlled trial with patients assigned to neuromuscular reversal with either sugammadex or neostigmine/glycopyrrolate reversal. The study will not be blinded to the anesthesiologist to allow for appropriate decision-making on timing and dosage of reversal. This is a single-center study.

Timeline

Start
2023-07-19
Primary completion
2024-07-05
Completion
2024-08-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Glycopyrrolate Small molecule 0.01 mg/kg
Comparator Neostigmine Other / unclassified 0.07 mg/kg
Subject Sugammadex Other / unclassified 2 mg/kg
Subject Sugammadex Other / unclassified 4 mg/kg

Indications